New hope for Hard-to-Treat breast cancer: drug combo trial launches
NCT ID NCT06042894
First seen Jun 24, 2026 · Last updated Jun 24, 2026
Summary
This Phase II trial tests two experimental drugs—SI-B003 alone or combined with BL-B01D1—in people with advanced HER2-negative breast cancer that has stopped responding to standard treatments. The study aims to see if these drugs can shrink tumors and determine the safest dose. About 58 participants will be enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, China
Contact
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
SI-B003 (an immunotherapy drug) and BL-B01D1 (a targeted chemotherapy drug)
What this could lead to
If successful, this could offer a new treatment option for people with advanced HER2-negative breast cancer who have run out of standard therapies.
What could go wrong
This is an early Phase II trial with only 58 participants, so results may not apply to everyone. The combination therapy may cause side effects or fail to shrink tumors.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.